NASDAQ:PRTK - Paratek Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $16.75
  • Forecasted Upside: 136.25 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.3 (-4.06%)

This chart shows the closing price for PRTK by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Paratek Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PRTK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PRTK

Analyst Price Target is $16.75
▲ +136.25% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Paratek Pharmaceuticals in the last 3 months. The average price target is $16.75, with a high forecast of $28.00 and a low forecast of $10.00. The average price target represents a 136.25% upside from the last price of $7.09.

This chart shows the closing price for PRTK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in Paratek Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/21/2021HC WainwrightBoost Price TargetBuy$22.00 ➝ $28.00High
4/29/2021WBB SecuritiesUpgradeSpeculative Buy ➝ Buy$10.00Low
4/23/2021WBB SecuritiesUpgradeSpeculative Buy ➝ Buy$6.00 ➝ $10.00Medium
3/4/2021SVB LeerinkReiterated RatingBuy$14.00High
3/2/2021Jefferies Financial GroupInitiated CoverageBuy$15.00Medium
2/8/2021HC WainwrightReiterated RatingBuyMedium
11/9/2020HC WainwrightBoost Price TargetBuy$19.00 ➝ $22.00High
8/11/2020HC WainwrightBoost Price TargetBuy$18.00 ➝ $19.00High
8/11/2020SVB LeerinkLower Price TargetOutperform$15.00 ➝ $14.00High
3/9/2020WedbushReiterated RatingOutperformHigh
2/26/2020HC WainwrightReiterated RatingBuyLow
1/27/2020SVB LeerinkReiterated RatingOutperformLow
1/8/2020WBB SecuritiesInitiated CoverageBuy$6.00Medium
1/2/2020Canaccord GenuityInitiated CoverageBuy$14.00Low
12/18/2019BTIG ResearchSet Price TargetBuy$36.00N/A
11/14/2019HC WainwrightLower Price TargetBuy$27.00 ➝ $18.00Low
11/4/2019HC WainwrightSet Price TargetBuy$27.00Medium
10/20/2019HC WainwrightReiterated RatingBuy$27.00Low
9/9/2019HC WainwrightSet Price TargetBuy$27.00High
6/26/2019HC WainwrightReiterated RatingBuyLow
5/9/2019WedbushReiterated RatingOutperform$17.00 ➝ $12.00High
5/9/2019LADENBURG THALM/SH SHReiterated RatingBuyHigh
3/18/2019Canaccord GenuitySet Price TargetBuy$25.00Low
3/6/2019WedbushReiterated RatingOutperformHigh
2/28/2019LADENBURG THALM/SH SHSet Price TargetBuy$18.00Medium
2/28/2019HC WainwrightReiterated RatingBuyHigh
1/16/2019Canaccord GenuityBoost Price TargetBuy$14.00 ➝ $25.00High
1/2/2019Canaccord GenuityInitiated CoverageBuy ➝ Buy$14.00High
12/18/2018LADENBURG THALM/SH SHReiterated RatingBuy$18.00Low
11/23/2018HC WainwrightLower Price TargetBuy ➝ Buy$55.00 ➝ $22.00Low
10/3/2018GuggenheimSet Price TargetBuy$26.00High
8/27/2018Bank of AmericaInitiated CoverageNeutral ➝ Neutral$13.00High
8/9/2018WedbushSet Price TargetBuy$20.00Low
8/2/2018Cantor FitzgeraldReiterated RatingBuy$50.00Low
6/11/2018Cantor FitzgeraldSet Price TargetBuy$50.00Low
5/9/2018Cantor FitzgeraldSet Price TargetBuy$50.00Low
4/5/2018Cantor FitzgeraldSet Price TargetBuy$50.00Low
3/4/2018SVB LeerinkReiterated RatingOutperformLow
3/2/2018HC WainwrightBoost Price TargetBuy ➝ Buy$43.00 ➝ $55.00High
3/2/2018Raymond JamesReiterated RatingStrong-Buy ➝ Outperform$36.00High
3/2/2018UBS GroupDowngradeStrong-Buy ➝ OutperformHigh
3/1/2018Cantor FitzgeraldSet Price TargetBuy$50.00High
1/3/2018Cantor FitzgeraldSet Price TargetBuy$50.00Low
10/24/2017Robert W. BairdReiterated RatingBuy$40.00N/A
10/24/2017GuggenheimInitiated CoverageBuy$44.00N/A
10/17/2017Cantor FitzgeraldSet Price TargetBuy$50.00N/A
9/21/2017Cantor FitzgeraldReiterated RatingBuy$50.00Low
8/24/2017Raymond JamesReiterated RatingStrong-Buy$36.00Medium
8/23/2017Cantor FitzgeraldReiterated RatingBuy$50.00High
8/8/2017Cantor FitzgeraldReiterated RatingOverweightHigh
7/18/2017HC WainwrightBoost Price TargetPositive ➝ Buy$36.00 ➝ $43.00High
7/17/2017Cantor FitzgeraldSet Price TargetBuy$50.00High
6/22/2017Cantor FitzgeraldReiterated RatingOverweight$50.00Medium
5/18/2017Raymond JamesInitiated CoverageStrong-Buy ➝ Strong-Buy$36.00High
5/4/2017Cantor FitzgeraldSet Price TargetBuy$33.00Low
4/24/2017Cantor FitzgeraldReiterated RatingBuy$32.00Low
4/11/2017HC WainwrightBoost Price TargetBuy ➝ Buy$33.00 ➝ $36.00Low
4/4/2017GuggenheimSet Price TargetBuy$38.00Medium
4/4/2017BTIG ResearchBoost Price TargetBuy$47.00 ➝ $56.00Medium
4/4/2017Robert W. BairdReiterated RatingOutperform$40.00Medium
4/3/2017WedbushReiterated RatingOutperform ➝ Outperform$30.00High
3/30/2017Cantor FitzgeraldReiterated RatingOverweight$32.00Medium
3/27/2017GuggenheimReiterated RatingBuyLow
3/27/2017Robert W. BairdReiterated RatingPositive$40.00High
3/3/2017Cantor FitzgeraldReiterated RatingOverweight$28.00N/A
12/22/2016BTIG ResearchInitiated CoverageBuy$47.00N/A
12/13/2016Robert W. BairdReiterated RatingPositive$40.00N/A
12/13/2016Cantor FitzgeraldSet Price TargetBuy$28.00N/A
11/20/2016Robert W. BairdSet Price TargetBuy$40.00N/A
11/3/2016SVB LeerinkReiterated RatingBuy$23.00N/A
11/2/2016Cantor FitzgeraldSet Price TargetBuy$28.00N/A
10/27/2016SVB LeerinkReiterated RatingOutperform$23.00N/A
8/16/2016GuggenheimReiterated RatingBuyN/A
8/16/2016HC WainwrightReiterated RatingBuyN/A
6/29/2016Cantor FitzgeraldReiterated RatingBuyN/A
(Data available from 6/21/2016 forward)
Paratek Pharmaceuticals logo
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. It also has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. The company was founded in 1996 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $7.09
Low: $7.06
High: $7.99

50 Day Range

MA: $8.36
Low: $7.16
High: $10.93

52 Week Range

Now: $7.09
Low: $4.11
High: $11.23


44,628 shs

Average Volume

491,260 shs

Market Capitalization

$332.72 million

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Paratek Pharmaceuticals?

The following Wall Street research analysts have issued stock ratings on Paratek Pharmaceuticals in the last twelve months: HC Wainwright, Jefferies Financial Group Inc., SVB Leerink LLC, WBB Securities, and Zacks Investment Research.
View the latest analyst ratings for PRTK.

What is the current price target for Paratek Pharmaceuticals?

4 Wall Street analysts have set twelve-month price targets for Paratek Pharmaceuticals in the last year. Their average twelve-month price target is $15.25, suggesting a possible upside of 106.4%. HC Wainwright has the highest price target set, predicting PRTK will reach $22.00 in the next twelve months. WBB Securities has the lowest price target set, forecasting a price of $10.00 for Paratek Pharmaceuticals in the next year.
View the latest price targets for PRTK.

What is the current consensus analyst rating for Paratek Pharmaceuticals?

Paratek Pharmaceuticals currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PRTK will outperform the market and that investors should add to their positions of Paratek Pharmaceuticals.
View the latest ratings for PRTK.

What other companies compete with Paratek Pharmaceuticals?

How do I contact Paratek Pharmaceuticals' investor relations team?

Paratek Pharmaceuticals' physical mailing address is 75 PARK PLAZA, BOSTON MA, 02116. The specialty pharmaceutical company's listed phone number is 617-807-6600 and its investor relations email address is [email protected] The official website for Paratek Pharmaceuticals is